$4.34
-4.4%Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
SGHT โข NASDAQ
| Sight Sciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-38.4M | -51.5M | -55.5M | -86.2M | -63M | -34.7M | -25.9M | -14.3M | |
487K | 712K | 614K | 710K | 632K | 554K | 295K | 63K | |
0.0 | 0.0 | 0.0 | 0.0 | 7.8M | 0.0 | 138K | 0.0 | |
13.1M | 17.1M | 14.6M | 13M | 5.1M | 497K | 118K | 52K | |
1.6M | 2.4M | 2.3M | 2.3M | 1.3M | 684K | 662K | 58K | |
-6.4M | 9M | -9.1M | -5.7M | -4.3M | 784K | -341K | -358K | |
-29.7M | -22.4M | -47.2M | -76M | -52.5M | -32.2M | -25M | -14.5M | |
INVESTING ACTIVITIES | ||||||||
-224K | -385K | -791K | -970K | -813K | -953K | -672K | -570K | |
-224K | -385K | -791K | -970K | -813K | -953K | -672K | -570K | |
FINANCING ACTIVITIES | ||||||||
1.8M | 1.1M | 1.3M | 1.2M | 256.7M | 0.0 | 0.0 | 0.0 | |
0.0 | 4.2M | 0.0 | 0.0 | 0.0 | 20.5M | 14M | 0.0 | |
-58K | -261K | -224K | 0.0 | -4.2M | -154K | -2.1M | -23K | |
1.8M | 5M | 1.1M | 1.2M | 252.5M | 73.4M | 42.7M | 12.2M | |
CASH FLOW SUMMARY | ||||||||
-28.1M | -17.8M | -46.9M | -75.7M | 199.2M | 40.3M | 17M | -2.8M | |
120.4M | 138.1M | 185M | 260.7M | 61.5M | 21.2M | 4.2M | 7.1M | |
92.2M | 120.4M | 138.1M | 185M | 260.7M | 61.5M | 21.2M | 4.2M | |
-29.9M | -22.7M | -48M | -76.9M | -53.4M | -33.1M | -25.7M | -15M |
SGHT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Continue your SGHT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.